Viewing nowSitalen 100 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Nexpharm Korea Co., Ltd.

MFDS item code 202005703 · Approved 2020.08.07 · Insurance code 662504560
Improvement of blood glucose control in type 2 diabetes
This medication is used to assist blood sugar control in patients with type 2 diabetes. Initially, it can be administered alone, but if adequate blood sugar control is difficult with monotherapy, it is administered in combination with metformin. Additionally, when blood sugar control is difficult with monotherapy of sulfonylurea, metformin, thiazolidinedione, or insulin, this medication can be used in combination to enhance therapeutic effects. Furthermore, when sufficient blood sugar control cannot be achieved even with combination therapies of sulfonylurea and metformin, thiazolidinedione and metformin, or insulin and metformin, this medication can be added to improve blood sugar control. Therefore, this medication plays a role in improving blood sugar control in various treatment situations.
This medication is administered at 100 mg once daily as monotherapy or combination therapy. The maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically during treatment. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.
This medication can cause severe allergic reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a doctor. This medication can cause a serious pancreatic inflammation called pancreatitis, so if symptoms such as abdominal pain or vomiting occur while taking it, notify medical staff promptly. Do not use in patients with type 1 diabetes or diabetic ketoacidosis, and also should not be administered in cases of allergy to the drug or its components. Patients with impaired kidney function may have difficulty excreting this medication, so dosage adjustments are necessary according to kidney function, and use must be done cautiously. Hypoglycemic symptoms can occur while taking this medication, especially when used together with insulin or sulfonylurea, so blood sugar levels should be checked frequently and hypoglycemia should be monitored. This medication may cause side effects such as upper respiratory infections, headaches, indigestion, and diarrhea, so if symptoms persist or worsen, consult with medical staff. It is advisable for pregnant or breastfeeding women not to use this medication, and safety and efficacy have not been established for children or adolescents under 18 years of age. Elderly patients should be assessed for potential kidney function decline before administration, and dosage adjustment may be necessary. In case of overdose, immediately visit a medical facility for appropriate treatment, and blood dialysis may be performed based on medical judgment as some may be removed during dialysis. This medication may have interactions with other hypoglycemic agents or specific medications, so all medications being taken should be reported to the medical staff.
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air exposure and kept at a temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medication for a longer period.
Light orange, round, double convex film-coated tablets
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Nexpharm Korea Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.